Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : GlaxoSmithKline Research and Development Limited
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the Morning, and GW685698X 200mcg and 400mcg Once Daily in the Evening Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (12 Years of Age and Older) with Persistent Asthma
The primary objective of this study is to evaluate the relative efficacy and safety of once daily and twice daily dosing and of morning and evening dosing of GW685698X in adolescent and adult subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A study to test possible drug interactions with a new drug for treating skin cancer
PART A-To evaluate the effect of repeat doses of GSK2118436 on the single dose PK of S-warfarin in subjects with BRAF mutant solid tumors. PART B & C-To evaluate the effect of repeat oral doses of an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy
The primary objective is to evaluate progression free survival (PFS) of ofatumumab maintenance treatment versus no further treatment after remission induction in subjects with relapsed Chronic Lymphoc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP)
To determine the efficacy of oral eltrombopag, when administered once daily, for 6 months duration, to previously treated adult subjects with chronic ITP
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
Mepolizumab for the treatment of severe asthma
The primary objective of this study is to describe the long-term safety profile of mepolizumab.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A study to assess the efficacy and safety of GSK2586184 in SLE
• To estimate the relationship between dose of GSK2586184 and pharmacodynamic effect on expression of selected messenger ribonucleic acid (mRNA) transcripts following 2 weeks of treatment in SLE patie...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor agonist, administered at 30, 50 and 75 mg as oral tablets once-daily for 6 weeks to adult male and female subjects with refractory, chronic immune thrombocytopenic purpura
To determine the efficacy of SB-497115-GR as a thrombopoietic agent, when administered once daily for 6 weeks to adult patients with refractory chronic ITP.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects
To demonstrate a superior renal safety profile in subjects receiving ABC/3TC FDC compared to TDF/FDC FDC, both administered with efavirenz
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn’s Disease
To induce clinical response (CDAI decrease from baseline ≥ 100 points) and/or remission (CDAI <150) following 12 weeks of treatment with one of two active doses of GSK1605786A for qualification of sub...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Limited
MAJ Il y a 5 ans
A three period study conducted at clinics in the US, Europe and South America to compare the effectiveness of different doses of a new investigational drug, GSK573719, with placebo (no active treatment) in subjects with mild asthma
The primary objective is to evaluate the dose response, efficacy and safety of five once daily doses of GSK573719 (15.6mcg, 31.25mcg, 62.5mcg, 125mcg and 250mcg). compared with placebo, over a minimu...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
1
2
3
4
Suivant